New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2012
13:51 EDTOREX, ARNA, VVUSVIVUS drug's CV profile viewed positively by FDA, says Rodman & Renshaw
After attending an FDA panel hearing focused on the effects of anti-obesity drugs on cardiovascular systems, Rodman & Renshaw believes that the FDA and the panel are comfortable with the cardiovascular profile of VIVUS' drug, Qnexa. The firm indicates that it doesn't expect the agency to require additional cardiovascular tests before Qnexa is approved, and it reiterates an Outperform rating on VIVUS.
News For VVUS;ARNA;OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
07:37 EDTOREXOrexigen and Takeda receive Paragraph IV certification notice
Subscribe for More Information
April 21, 2015
16:32 EDTVVUSVIVUS granted patents covering Qsymia compositions and methods
Subscribe for More Information
14:02 EDTOREXParagraph IV patent challenges submitted to FDA for Orexigen's Contrave
An Abbreviated New Drug Application, or ANDA, has been received by the Office of Generic Drugs containing a "Paragraph IV" patent certification for Contrave, the weight loss drug whose patent is owned by Orexigen Therapeutics, according to an FDA notice. The date on which the first substantially complete generic drug application was submitted to the Agency for Contrave was March 12, according to the posting. Reference Link
April 20, 2015
10:03 EDTVVUSHigh option volume stocks
Subscribe for More Information
April 15, 2015
19:34 EDTVVUSVIVUS files patent infringement lawsuit against Teva
Subscribe for More Information
April 14, 2015
07:10 EDTVVUSVIVUS says CVOT 'unlikely to initiate' in 2015
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use